CXCR2 and hepatocellular carcinoma: Therefore, in this study, the results suggest that combined treatment with DOX and anti-CXCR2 antibody can block the pNF-κB/IL-1β signalling pathway to alter the secretion of CXCL1 and influence EMT in HCC cells and M2 macrophages.